NCT04001777 - A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 4, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

EGFR Positive Non-small Cell Lung Cancer

Interventions

DRUG

APG-1252

Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.

DRUG

Osimertinib Mesylate Tablets

Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression

Trial Locations (4)

Sun-Yat Sen University Cancer Center, Guangzhou

Henan Provincial people's Hospital, Zhengzhou

First Hospital of Jilin University, Changchun

Jilin Provincial Cancer Hospital, Changchun